Community Academic Profiles - Faculty & Researchers

Bio

Clinical Focus

Hematology, Pediatric
Oncology (Cancer), Pediatric
Pediatric Hematology-Oncology

Academic Appointments

Professor, Pediatrics - Stem Cell Transplantation
Member, Bio-X
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute

Professional Education

Board Certification: American Board of Pediatrics, Pediatrics (1984)
Residency: Montefiore Medical Center - Albert Einstein College of Medicine (1982) NY
Internship: Montefiore Medical Center - Albert Einstein College of Medicine (1979) NY
Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (1984)
Fellowship: Children's Hospital Los Angeles (1985) CA
Medical Education: Stanford University Medical Center (1978) CA

Research & Scholarship

Clinical Trials

Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation Recruiting

This project allows for the systematic collection and analysis of long-term follow-up clinical parameters in children who have received a stem cell transplant. The data collected will assist in determining appropriate intervention and treatment plans for patients enrolled on this study. In addition, future patients may benefit by having the ability to anticipate problems and develop methods of prevention or early intervention.

View full details
A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses Not Recruiting

CMX001 is an orally administered lipid conjugate of the synthetic nucleotide analog cidofovir (CDV). The conjugate is believed to be absorbed in the small intestine then delivered to target organs throughout the body where it crosses cell membranes by facilitated and passive diffusion. Inside the cell, CMX001 is cleaved by intracellular phospholipases to release CDV which is converted to the active antiviral agent, CDV-diphosphate (CDV-PP), by intracellular anabolic kinases. Adults and adolescents, regardless of viral infection/disease, will have a maximum weekly dose of 200 mg i.e., 200 mg once weekly OR 100 mg twice weekly; not to exceed 4mg/kg total weekly dose. Pediatric subjects (< 12 years), regardless of viral infection/disease, will have a maximum weekly dose of 4 mg/kg i.e., 4 mg/kg once weekly OR 2 mg/kg twice weekly.

Stanford is currently not accepting patients for this trial. For more information, please contact Julia Buckingham, (650) 736 - 1556.

View full details
Allogeneic Transplantation From Related Haploidentical Donors Not Recruiting

The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).

Stanford is currently not accepting patients for this trial. For more information, please contact BMT Referrals, (650) 723 - 0822.

View full details
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Not Recruiting

The study is designed as a Phase III, randomized, open label, multicenter, prospective, comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) versus marrow from unrelated donors for transplantation in patients with hematologic malignancies. Recipients will be stratified by transplant center and disease risk and will be randomized to either the PBSC or marrow arm in a 1:1 ratio.

Stanford is currently not accepting patients for this trial. For more information, please contact Kate Tierney, (650) 725 - 7063.

View full details
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Not Recruiting

Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the course of this study, it will be evaluated whether a particular type of blood cell, called a cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation. CIK cells are present in small quantities in the bloodstream but their numbers can be expanded after a brief period of nurturing in a laboratory.

Stanford is currently not accepting patients for this trial. For more information, please contact Physician Referrals, 650-723-0822.

View full details
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Not Recruiting

The study is designed as a phase III, randomized, open label, multicenter, prospective, comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis after human leukocyte antigen (HLA)-matched, related, peripheral blood stem cell transplantation in individuals with hematologic cancer. Participants will be stratified by transplant center and will be randomly assigned to the sirolimus/tacrolimus or tacrolimus/methotrexate arms at a 1:1 ratio.

Stanford is currently not accepting patients for this trial. For more information, please contact BMT Referrals, (650) 723 - 0822.

View full details
The Adv Halt Trial Not Recruiting

The primary objective of this study is to evaluate the safety and efficacy of preemptive treatment with CMX001 versus placebo for the prevention of AdV disease in recipients of HSCT with asymptomatic AdV viremia.

Stanford is currently not accepting patients for this trial. For more information, please contact Julia Buckingham, (650) 736 - 1556.

View full details

Teaching

COVID-19 Updates

Stanford Medicine is closely monitoring the outbreak of novel coronavirus (COVID-19). A new page is dedicated to the latest information and developments about COVID-19.

Follow Stanford Medicine

��

Health Care

Healing through compassion and world-class science

Research

Fueling discovery and innovation to advance human health

Education

Empowering tomorrow's leading physicians and scientists

Faculty

Students

Community

RACIAL JUSTICE

Our Pledge

Racism and discrimination are direct affronts to Stanford Medicine?s values. Read our leaders? pledge on racial equity.

About
Stanford Medicine

A leader in the biomedical revolution, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies.

Eventful first year at new hospital

The 368-bed hospital building, which celebrates its one-year anniversary on Nov. 17, features technology and design features that have made handling COVID-19 cases easier.

covid-19 research at Stanford Medicine

Our scientists have launched dozens of research projects as part of the global response to COVID-19. Some aim to prevent, diagnose and treat the disease; others aim to understand how it spreads and how people?s immune systems respond to it.

innovation

Kenneth Weinberg

Anne T. and Robert M. Bass Professor in Pediatric Cancer and Blood Diseases

Pediatrics - Stem Cell Transplantation

Bio

Clinical Focus

Academic Appointments

Professional Education

Contact

Research & Scholarship

Clinical Trials

Teaching

2020-21 Courses

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources

COVID-19 Updates

Follow Stanford Medicine

Health Care

Research

Education

Our Pledge

About
Stanford Medicine

Eventful first year at new hospital

How to bounce back from the pandemic

Disparities in COVID-19 hospitalizations

Breaking COVID-19's deadly embrace

Site Navigation:

Footer Links:

Stanford Medicine Resources:

Kenneth Weinberg

Anne T. and Robert M. Bass Professor in Pediatric Cancer and Blood Diseases

Pediatrics - Stem Cell Transplantation

Bio

Clinical Focus

Academic Appointments

Professional Education

Contact

Research & Scholarship

Clinical Trials

Teaching

2020-21 Courses

You are Here:

Current Tab: 6

COVID-19 Updates

Follow Stanford Medicine

Health Care

Research

Education

Our Pledge

AboutStanford Medicine

Eventful first year at new hospital

How to bounce back from the pandemic

Disparities in COVID-19 hospitalizations

Breaking COVID-19's deadly embrace

Site Navigation:

Footer Links:

Stanford Medicine Resources:

About
Stanford Medicine